These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

662 related articles for article (PubMed ID: 9029114)

  • 41. Activation of the alternative complement pathway by EBV and the viral envelope glycoprotein, gp350.
    Mold C; Bradt BM; Nemerow GR; Cooper NR
    J Immunol; 1988 Jun; 140(11):3867-74. PubMed ID: 2836501
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Chemotactic activity derived from interaction of factors D and B of the properdin pathway with cobra venom factor or C3B.
    Ruddy S; Austen KF; Goetzl EJ
    J Clin Invest; 1975 Mar; 55(3):587-92. PubMed ID: 1167871
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Implications for herpes simplex virus vaccine strategies based on antibodies produced to herpes simplex virus type 1 glycoprotein gC immune evasion domains.
    Chang YJ; Jiang M; Lubinski JM; King RD; Friedman HM
    Vaccine; 2005 Sep; 23(38):4658-65. PubMed ID: 15936852
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immune evasion of Moraxella catarrhalis involves ubiquitous surface protein A-dependent C3d binding.
    Hallström T; Nordström T; Tan TT; Manolov T; Lambris JD; Isenman DE; Zipfel PF; Blom AM; Riesbeck K
    J Immunol; 2011 Mar; 186(5):3120-9. PubMed ID: 21270401
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The role of immunoglobulins in alternative pathway activation by zymosan. II. The effect of IgG on the kinetics of the alternative pathway.
    Schenkein HA; Ruddy S
    J Immunol; 1981 Jan; 126(1):11-5. PubMed ID: 6905857
    [No Abstract]   [Full Text] [Related]  

  • 46. A new activity of complement component C3: cell-bound C3b potentiates lysis of erythrocytes by C5b,6 and terminal components.
    Hammer CH; Abramovitz AS; Mayer MM
    J Immunol; 1976 Sep; 117(3):830-4. PubMed ID: 956655
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Receptor-binding sites on C3 and C3b.
    Dierich MP; Bokisch VA
    J Immunol; 1977 Jun; 118(6):2145-50. PubMed ID: 864256
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Initiation of the alternative pathway of complement: recognition of activators by bound C3b and assembly of the entire pathway from six isolated proteins.
    Schreiber RD; Pangburn MK; Lesavre PH; Müller-Eberhard HJ
    Proc Natl Acad Sci U S A; 1978 Aug; 75(8):3948-52. PubMed ID: 279011
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Characterization of three monoclonal antibodies against C3 with selective specificities.
    Iida K; Mitomo K; Fujita T; Tamura N
    Immunology; 1987 Nov; 62(3):413-7. PubMed ID: 2444528
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The role of properdin in the assembly of the alternative pathway C3 convertases of complement.
    Hourcade DE
    J Biol Chem; 2006 Jan; 281(4):2128-32. PubMed ID: 16301317
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Compstatin inhibits complement activation by binding to the beta-chain of complement factor 3.
    Soulika AM; Holland MC; Sfyroera G; Sahu A; Lambris JD
    Mol Immunol; 2006 May; 43(12):2023-9. PubMed ID: 16472861
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Formation and composition of the C3 activating enzyme complex of the properdin system. Sequential assembly of its components on solid-phase trypsin-agarose.
    Vogt W; Schmidt G; Dieminger L; Lynen R
    Z Immunitatsforsch Exp Klin Immunol; 1975 Jul; 149(5):440-55. PubMed ID: 126576
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Human alternative complement pathway: membrane-associated sialic acid regulates the competition between B and beta1 H for cell-bound C3b.
    Kazatchkine MD; Fearon DT; Austen KF
    J Immunol; 1979 Jan; 122(1):75-81. PubMed ID: 762425
    [No Abstract]   [Full Text] [Related]  

  • 54. Activation of the alternative complement pathway with rabbit erythrocytes by circumvention of the regulatory action of endogenous control proteins.
    Fearon DT; Austen KF
    J Exp Med; 1977 Jul; 146(1):22-33. PubMed ID: 559720
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Characterization of herpes simplex virus type 1 recombinants that express and incorporate high levels of HCV E2-gC chimeric proteins.
    Kouvatsis V; Argnani R; Tsitoura E; Arsenakis M; Georgopoulou U; Mavromara P; Manservigi R
    Virus Res; 2007 Jan; 123(1):40-9. PubMed ID: 16989918
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Characterization of glycoprotein C of HSZP strain of herpes simplex virus 1.
    Oravcová I; Kúdelová M; Mlcuchová J; Matis J; Bystrická M; Westra DF; Welling-Wester S; Rajcáni J
    Acta Virol; 2000 Apr; 44(2):99-108. PubMed ID: 10989701
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Interaction of vaccinia virus complement control protein with human complement proteins: factor I-mediated degradation of C3b to iC3b1 inactivates the alternative complement pathway.
    Sahu A; Isaacs SN; Soulika AM; Lambris JD
    J Immunol; 1998 Jun; 160(11):5596-604. PubMed ID: 9605165
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Role of the C3b-binding site on C4b-binding protein in regulating classical pathway C5 convertase.
    Rawal N; Pangburn MK
    Mol Immunol; 2007 Feb; 44(6):1105-14. PubMed ID: 16979240
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A molecular concept of the properdin pathway.
    Medicus RG; Schreiber RD; Götze O; Müller-Eberhard HJ
    Proc Natl Acad Sci U S A; 1976 Feb; 73(2):612-6. PubMed ID: 54923
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Herpes simplex virus glycoproteins gC-1 and gC-2 bind to the third component of complement and provide protection against complement-mediated neutralization of viral infectivity.
    McNearney TA; Odell C; Holers VM; Spear PG; Atkinson JP
    J Exp Med; 1987 Nov; 166(5):1525-35. PubMed ID: 2824652
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.